Approved December 2002
Relpax (eletriptan hydrobromide), novel a triptan, relieves pain in nerve endings and associated symptoms caused by migraine headaches.
Relpax was shown to be effective at doses of 20 mg, 40 mg and 80 mg. The maximum recommended single dose of Relpax is 40 mg.
Relpax should not be used by patients with severe hepatic impairment. Relpax tablets should not be used within at least 72 hours with potent CYP3A4 inhibitors.
Approval for Replax was based on 10 randomized, double-blind clinical studies. More than 9,000 patients participated in the clinical trials and more than 70,000 migraine attacks were treated .
Relpax was effective in relieving migraine pain and the associated symptoms of nausea and sensitivity to light and sound. The drug has a rapid onset of action(as early as 30 minutes), superior efficacy, and a lower headache recurrence rate than those reported for other triptans.
Adverse events associated with the use of Relpax may include (but are not limited to) the following:
Relpax is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist that acts at serotonin 5HT1B receptors on intracranial blood vessels and 5HT1D receptors on sensory nerve endings to relieve the pain and associated symptoms of a migraine attack.
The Relpax (eletriptan hydrobromide) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.